Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.15Last Year’s EPS
0.25Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -12.55%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
Corcept Therapeutics demonstrated strong financial performance with significant revenue and net income growth. The company made substantial progress in drug development, notably with relacorilant for hypercortisolism and potential cancer treatments. However, they faced operational challenges affecting revenue and a legal setback with Teva. Despite these issues, the overall outlook remains positive due to strategic advancements and strong financials.Company Guidance
During the Corcept Therapeutics conference call, the company provided guidance for 2025, projecting revenue between $900 million and $950 million, reflecting continued growth following a 40% increase in 2024 revenue to $675 million. Net income rose by 33% to $141 million in 2024. The company also highlighted its robust cash and investments, which totaled $603 million at the end of 2024, up from $425 million the previous year. Additionally, Corcept repurchased $38 million of its common stock during 2024. The call also discussed the potential market impact of their drug relacorilant and ongoing legal proceedings with Teva related to patent issues.Record Revenue Growth
Corcept Therapeutics reported 2024 revenue of $675 million, marking a 40% increase compared to the previous year. They expect continued growth with 2025 revenue guidance of $900 million to $950 million.
Strong Net Income Performance
Net income for 2024 was $141 million, representing a 33% increase compared to the prior year.
Successful Stock Repurchase
The company acquired $38 million of its common stock as part of its stock repurchase program.
Promising Drug Development
Corcept submitted a new drug application for relacorilant, with promising results from GRACE, GRADIENT, and Phase II studies showing statistically significant improvements in patient outcomes.
Positive CATALYST Study Results
The CATALYST study showed that 1 in 4 patients with difficult to control type 2 diabetes has hypercortisolism. Patients receiving Korlym exhibited a significant reduction in hemoglobin A1c compared to placebo.
Strategic Advancements in Cancer Treatment
Corcept is conducting the ROSELLA study to evaluate relacorilant’s potential in treating platinum-resistant ovarian cancer, with positive Phase II trial results suggesting improved progression-free survival.
Strong Financial Position
Corcept ended 2024 with $603 million in cash and investments, compared to $425 million at the end of the previous year.
---
CORT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CORT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $63.37 | $59.85 | -5.55% |
| Oct 30, 2024 | $46.89 | $48.97 | +4.44% |
| Jul 29, 2024 | $36.53 | $36.12 | -1.12% |
| May 01, 2024 | $23.88 | $25.06 | +4.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Corcept Therapeutics Inc. (CORT) report earnings?
Corcept Therapeutics Inc. (CORT) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Corcept Therapeutics Inc. (CORT) earnings time?
Corcept Therapeutics Inc. (CORT) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CORT EPS forecast?
CORT EPS forecast for the fiscal quarter 2025 (Q1) is 0.15.
---